We are international

Elotuzumab (formerly known as HuLuc63) is a monoclonal antibody that targets CS1, a cell surface glycoprotein highly expressed on myeloma cells but minimally expressed on normal cells. Elotuzumab is currently in clinical trials for newly diagnosed, previously untreated and relapsed or refractory myeloma.

05.27.15  Expanded Access Treatment Protocol CA204-143
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.

ClinicalTrials.gov Identifier:
NCT02368301 more..